QIAGEN und Bode Technology treiben Nutzung der GEDmatch PRO Datenbank für forensische genetische Genealogie voran
23 sept. 2024 16h05 HE
|
QIAGEN N.V.
VENLO, Niederlande, und GERMANTOWN, Maryland, USA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass Bode Technology, das...
QIAGEN erweitert Portfolio für digitales PCR-System QIAcuity um über 100 neue Assays auf seiner GeneGlobe‑Plattform
18 sept. 2024 16h05 HE
|
QIAGEN N.V.
VENLO, Niederlande, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute mit der Einführung von 100 neuen Assays für seine digitale PCR (dPCR)-Plattform...
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform
18 sept. 2024 16h05 HE
|
QIAGEN N.V.
Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital...
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs
12 sept. 2024 16h05 HE
|
QIAGEN N.V.
Venlo, the Netherlands, Rio de Janeiro, Brazil, Sept. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its strategic partnership with...
QIAGEN und Bio-Manguinhos/Fiocruz verbessern Nachweis von Malaria und Dengue-Fieber in Brasiliens nationalem Screening-Programm
12 sept. 2024 16h05 HE
|
QIAGEN N.V.
Moderne PCR-basierte Screening-Plattform kommt landesweit in 30 Laboren zum Einsatz und bietet neue Möglichkeiten zum Nachweis von Malaria, HIV, HCV und HBV in Blutspenden // Modernste Funktionen...
QIAGEN und Lilly kooperieren bei der Entwicklung eines QIAstat-Dx IVD-Panels zur Identifizierung von Patienten mit erhöhtem Risiko für Alzheimererkrankungen
04 sept. 2024 16h05 HE
|
QIAGEN N.V.
VENLO, Niederlande, Sept. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute eine Kooperation mit Eli Lilly and Company zur Unterstützung bei der Entwicklung...
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease
04 sept. 2024 16h05 HE
|
QIAGEN N.V.
Venlo, the Netherlands, Sept. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a collaboration with Eli Lilly and Company to...
QIAGEN N.V. announces conversion price of new net share settled convertible bonds
03 sept. 2024 17h05 HE
|
QIAGEN N.V.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
QIAGEN N.V. announces successful placement of new net share settled convertible bonds
03 sept. 2024 11h00 HE
|
QIAGEN N.V.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
03 sept. 2024 02h36 HE
|
QIAGEN N.V.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...